These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples. Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats. Pehrsson S; Johansson K; Kjaer M; Elg M Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126 [TBL] [Abstract][Full Text] [Related]
13. In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban. He S; Wallèn H; Bark N; Blombäck M J Thromb Thrombolysis; 2013 Feb; 35(2):131-9. PubMed ID: 22843196 [TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial. Kurtoglu M; Koksoy C; Hasan E; Akcalı Y; Karabay O; Filizcan U; J Vasc Surg; 2010 Nov; 52(5):1262-70. PubMed ID: 20732787 [TBL] [Abstract][Full Text] [Related]
15. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. Clemens A; van Ryn J; Sennewald R; Yamamura N; Stangier J; Feuring M; Härtter S Eur J Clin Pharmacol; 2012 May; 68(5):607-16. PubMed ID: 22252796 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial. Anderson JA; Hirsh J; Yusuf S; Johnston M; Afzal R; Mehta SR; Fox KA; Budaj A; Eikelboom JW J Thromb Haemost; 2010 Feb; 8(2):243-9. PubMed ID: 19943881 [TBL] [Abstract][Full Text] [Related]
17. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism. Halton JML; Picard AC; Harper R; Huang F; Brueckmann M; Gropper S; Maas H; Tartakovsky I; Nurmeev I; Mitchell LG; Brandão LR; Chalmers E; Albisetti M Thromb Haemost; 2017 Nov; 117(11):2168-2175. PubMed ID: 29202215 [TBL] [Abstract][Full Text] [Related]
20. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P; Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]